EvE Bio is now integrated into DrugBank, creating the largest public resource of drug–protein interactions and making off-target biology searchable, connected, and actionable for the first time.
Most approved drugs interact with dozens of proteins — sometimes hundreds — beyond their intended targets. These off-target interactions drive side effects, adherence issues, and treatment discontinuation, but when mapped systematically they allow researchers to re-evaluate clinical observations, uncover the mechanisms behind adverse events, and identify new therapeutic opportunities grounded in biology.
Mode / target / compound
EvE Bio's dataset provides experimental measurements of how approved small molecules interact with major target classes including GPCRs, kinases, and nuclear receptors. Each interaction is tested using standardized biochemical and cell-based assays to distinguish true actives from non-specific or frequent hitters. Integrated into DrugBank's knowledge graph, this large-scale dataset connects binding activity to pathways, diseases, and clinical trials — transforming previously isolated experimental data into a searchable, connected, and actionable resource.
Number of drug-protein interactions with drugs grouped by indicated therapeutic area. Counted across EvE Bio and DrugBank together.
The interaction map is drawn in your browser from the published dataset.
A new adverse event emerges in post-market surveillance. Which off-target interactions could explain it? Pull the drug's interaction profile across receptor classes, review quantified activity alongside cell-viability data, and pinpoint potential molecular drivers. By connecting these results to pathways, diseases, and trials, DrugBank helps teams generate mechanistic hypotheses and plan follow-up validation faster.
Which approved drugs show activity at your target of interest? Filter for agonists or antagonists within EvE Bio's screened targets, exclude compounds with cytotoxic signals, and prioritize by selectivity. Results highlight drugs with known safety profiles and relevant activity — ideal starting points for proof-of-concept studies or repositioning campaigns.
When a drug shows an unexpected effect or safety signal, explore its off-target interaction profile to identify which receptors may be responsible. By linking those targets to pathways, diseases, and known outcomes, researchers can generate testable hypotheses about underlying mechanisms and guide smarter clinical or preclinical investigations.
EvE Bio is a focused research organization (FRO) on a mission to map the pharmome — the complete network of interactions between approved drugs and human proteins. Through systematic, high-throughput experimental screening, EvE Bio generates rigorously validated drug-target interaction data and releases it publicly under a Creative Commons license, free for academic use and available for commercial licensing.
Learn more about EvE Bio
EvE Bio releases the pharmome under a Creative Commons license — free for academic use, and available for commercial licensing through DrugBank.
Free
Access EvE Bio's dataset through DrugBank's open-science program for academic or non-commercial use. Ideal for universities, research institutes, and non-profit projects.
Request to join DrugBank for AcademiaLicensed
Access EvE Bio's full dataset within DrugBank's knowledge graph. Query across drugs, targets, and trials, export structured data, and integrate results into your analytics or discovery pipelines.
Filtering and visualization by activity, potency and target class are coming soon to DrugBank.
Contact SalesEmail us at partnerships@drugbank.com to explore integration and commercial licensing options.
EvE Bio uses standardized assays (β-arrestin, TR-FRET) across GPCRs, kinases, and nuclear receptors. Results include potency metrics (pXC50) and quality flags for frequent hitters and cytotoxic effects.
Yes. Commercial licensing is available through EvE Bio and DrugBank for enterprise or AI/ML model training applications.